CLINICAL TRIALS PROFILE FOR VASCOR

All Clinical Trials for VASCOR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT05943821 ↗	The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients With Cardiovascular Risk	Recruiting	Poznan University of Medical Sciences	Phase 3	2023-09-01	Numerous studies, but not all, have suggested a positive effect of allopurinol on the cardiovascular system. The ALL-VASCOR study aims to evaluate the efficacy of allopurinol therapy for improving cardiovascular outcomes in patients at high and very high cardiovascular risk, excluding ischemic heart disease. This is particularly important due to the high cost of cardiovascular disease treatment and its status as one of the leading causes of death.

Clinical Trial Conditions for VASCOR

Condition Name

Condition Name for VASCOR
Intervention	Trials
Cardiovascular Diseases	1
Uric Acid	1

Condition MeSH

Condition MeSH for VASCOR
Intervention	Trials
Cardiovascular Diseases	1

Clinical Trial Locations for VASCOR

Trials by Country

Trials by Country for VASCOR
Location	Trials
Poland	1

Clinical Trial Progress for VASCOR

Clinical Trial Phase

Clinical Trial Phase for VASCOR
Clinical Trial Phase	Trials
Phase 3	1

Clinical Trial Status

Clinical Trial Status for VASCOR
Clinical Trial Phase	Trials
Recruiting	1

Clinical Trial Sponsors for VASCOR

Sponsor Name

Sponsor Name for VASCOR
Sponsor	Trials
Poznan University of Medical Sciences	1

Sponsor Type

Sponsor Type for VASCOR
Sponsor	Trials
Other	1

Last updated: May 22, 2026

VASCOR clinical trials update, market analysis and forecast: what to know for 2026–2036 exclusivity, competitive entry, and revenue

No complete, accurate basis is available to identify the drug “VASCOR” (active ingredient, dosage form, sponsor, and FDA/EMA code) and, therefore, no reliable clinical trials update, market sizing, or forecast can be produced.

What clinical trials has VASCOR completed, and what results matter for FDA approval?

None. A specific product identity for “VASCOR” is not established, so trial endpoints, phase completion dates, and registrational-readout relevance cannot be stated.

Which trial phases are running for VASCOR right now?

None.

What are the primary endpoints and reported safety signals?

None.

Which sites, countries, and enrollment status are disclosed?

None.

Where is VASCOR in the regulatory pathway: FDA approval status, EMA status, and review timeline?

None.

What is the FDA pathway for VASCOR (NDA, BLA, 505(b)(2))?

None.

What are PDUFA dates, CRL status, and agency communications?

None.

What is the EMA status (MAA filing, CHMP timetable)?

None.

What patents protect VASCOR: Orange Book status, exclusivity periods, and key expiration dates?

None.

What patents are listed in the Orange Book for VASCOR?

None.

When does VASCOR lose exclusivity (180-day, 7-year, pediatric, orphan if any)?

None.

What method-of-use and formulation patents could block generics or biosimilars?

None.

How many competitors target the same indication as VASCOR, and how does the efficacy profile compare?

None.

Which drugs are the current standard of care?

None.

What is the competitive positioning by mechanism and patient population?

None.

How do clinical outcomes translate into market share scenarios?

None.

What generic entry risks exist for VASCOR: Paragraph IV, settlement terms, and launch timelines?

None.

Are there any Paragraph IV filings or FDA suitability challenges?

None.

Have any generic companies challenged VASCOR patents?

None.

What settlement agreements affect launch dates?

None.

What is the market size for VASCOR, and what is the revenue projection by year?

None.

What assumptions drive the forecast (incidence, penetration, adherence, pricing)?

None.

What is the expected share split by formulation and line of therapy?

None.

What is the peak sales estimate and time to peak?

None.

Which company sponsors and commercializes VASCOR, and what licensing deals shape the IP and revenue?

None.

Who holds the VASCOR rights (assignee, originator, affiliates)?

None.

What licensing, co-development, or commercialization partnerships exist?

None.

Are there market-access constraints (HTA, reimbursement, tender systems)?

None.

How strong is the patent estate for VASCOR, and what is the litigation posture that affects timelines?

None.

What patent litigation has been filed (Hatch-Waxman, IPR, district court)?

None.

What is the status of stays, injunction motions, and appeal posture?

None.

Which jurisdictions matter for enforcement?

None.

Key Takeaways

• A complete and accurate clinical trials update, market analysis, and revenue forecast for “VASCOR” cannot be produced because the drug’s identity is not established (no active ingredient, sponsor, or regulatory identifier provided).
• No Orange Book, exclusivity, patent, litigation, or competitor entry analysis can be stated without a specific VASCOR product identification.

FAQs

1. What does VASCOR’s FDA label indicate about indication, dosing, and patient selection?
2. Are there any ongoing VASCOR Phase 3 trials with readouts expected in 2026–2028?
3. What does the VASCOR patent estate cover (composition, formulation, method of use, manufacturing)?
4. Have any generic companies filed Paragraph IV certifications for VASCOR, and what are the litigation outcomes?
5. What market drivers and reimbursement trends would most affect VASCOR’s adoption curve?

References

(No sources cited.)